Clinical Trial Update: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). [Phase 1, Phase 2]

View source ↗

Summary

The OMNIA-1 study evaluated ANV419 alone or with approved treatment in melanoma (including cutaneous/metastatic disease) in Phase 1/2; the trial is completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ANV419

Snippet

Sponsor: Anaveon AG | Conditions: Melanoma (Skin), Cutaneous Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-08-26